The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
Antib Ther
.
2019 Mar 13;2(2):54-55.
doi: 10.1093/abt/tbz005.
eCollection 2019 Apr.
Author
Mi Deng
1
Affiliation
1
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
PMID:
33928222
PMCID:
PMC7990150
DOI:
10.1093/abt/tbz005
No abstract available
Keywords:
PD-1 antibody; Sintilimab; checkpoint inhibitor; classic Hodgkin's lymphoma.
Publication types
News